Navigation Links
PTC Therapeutics Expands Management Team
Date:10/1/2013

s in other industries including: New York Life Insurance Company and Altria Corporate Services, Inc. Mr. Rexroad received an M.S. in Business Administration focusing on Human Resources and Labor Relations and a B.S. in Business Management from Virginia Tech.

"I am delighted to join PTC at this exciting time in the company's history," stated Mr. Martin Rexroad, Senior Vice President, Human Resources, PTC Therapeutics, Inc. "PTC is at a critical stage of its development, as a newly public company with lead product candidates in late-stage clinical trials. I look forward to being part of PTC's growth and development. The culture of innovation, collaboration and high scientific standards at PTC is parallel only to its commitments to patients and creates a remarkable work environment."

Mr. R.A. Session II returns to PTC to work cross-functionally in corporate strategy, commercial development and finance. Prior to joining PTC, Mr. Session was Senior Director, Strategic Planning & Finance at Reata Pharmaceuticals where he led strategic analytics, valuation analysis, market access, pricing and long-range planning. Mr. Session was an integral part of the deal teams that successfully completed two of the largest licensing transactions in pharmaceutical history. Prior to Reata, Mr. Session served as Associate Director Strategic Planning & Finance at PTC from 2008 to 2010. Mr. Session has held various positions in strategic planning, drug development, and commercialization at other leading pharmaceutical companies including: AstraZeneca and Johnson & Johnson. He holds an MBA and MSF from Texas A&M University at Commerce, College of Business and Technology and a B.S. from the University of North Carolina at Charlotte, Belk College of Business.

Dr. Jay Barth leads PTC's clinical team and oversees all clinical trials at the company. Dr. Barth joined PTC in 20
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
(Date:8/27/2014)... survive impact by the huge amounts of energy ... energy for photosynthesis. The hypothesis is that the ... the energy throughout the entire protein molecule through ... now managed to successfully ,film, this process. , ... which play a role in photosynthesis and thus ...
(Date:8/27/2014)... , Aug. 27, 2014  A novel ... to help physicians better identify early-stage disease, when ... disability, according to a new study in The ... Diagnostics (NYSE: DGX ) and other ... 14-3-3eta protein outperformed conventional antibody-serum testing, including rheumatoid ...
(Date:8/27/2014)... DUBLIN , Aug. 27, 2014 ... the "Global Enzyme for Pulp & Paper Industry ... The Global Enzyme for Pulp & Paper Industry ... the current state of the global enzyme for pulp ... basic overview of the industry including definitions, classifications, applications ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3DTU researchers film protein quake for the first time 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Global Enzyme for Pulp & Paper Industry Report 2014 2
... Inc.,(OTC Bulletin Board: NGNM) announced today that it plans ... July 31, 2008., The Company has scheduled ... results on July 31, 2008, at 11:00 AM EDT. ... 689-8033 (international) at least,five minutes prior to the call. ...
... James C. Powell, former,President and Chief Operating Officer ... of Nerites Corporation., Under Powell,s guidance, SurModics ... partnerships to commercialize products.,Powell joined SurModics in 1987 ... lead the company,s transition from a diagnostics kit,manufacturer ...
... VEGAS, July 29 American Pacific,Corporation (Nasdaq: APFC ... third quarter financial results on Tuesday, August 5, 2008. ... to participate in,a teleconference to review the financial results ... held Tuesday, August 5, 2008 at 1:30 p.m.,PDT. To ...
Cached Biology Technology:NeoGenomics Schedules its Q2 2008 Earnings Release for July 31, 2008 2James C. Powell Joins Nerites Board of Directors 2American Pacific to Release Financial Results and Hold Fiscal 2008 Third Quarter Investor Teleconference 2
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... Society of Human Genetics from October 18 22, ... meant to promote the entry of students, post doctorates ... the basic science community and to encourage the participation ... Genetics. This year MARC conferred 16 awards totaling ...
(Date:8/28/2014)... have identified the developmental on-off switch for Streptomyces ... than two-thirds of the world,s naturally derived antibiotic medicines. ... whether it is possible to manipulate this switch to ... study, appearing August 28 in Cell , found ... cyclic-di-GMP and a larger protein called BldD ultimately controls ...
(Date:8/28/2014)... measuring and imaging how quickly blood flows in the ... drug abuse affects the brain, which may aid in ... better treatment options for recovering drug addicts. The new ... Brook University in New York, USA and the U.S. ... Optical Society,s (OSA) open-access journal Biomedical Optics ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3
... 3 fatty acids in fish oils have been well documented ... and reducing methane emissions. These last two benefits may ... the environment, as methane given off by farm animals is ... March) researchers from University College Dublin reported that by including ...
... years because of an inherited cardiac arrhythmia syndrome ... thanks to a discovery made by Vanderbilt University Medical ... M.D., Ph.D., report this week in Nature Medicine ... lethal arrhythmias in patients with a specific type of ...
... study,s findings appear to echo the insect worlds portrayed in ... characters live in rigidly conformist societies. Scientists from the ... a mathematical model to study the manner in which cooperative ... study identifies that there are two scenarios in which a ...
Cached Biology News:Targeted drug therapy prevents exercise-induced arrhythmias 2Targeted drug therapy prevents exercise-induced arrhythmias 3
... Membrane Protein 2, Synaptobrevin 2). ... homology with any other known ... expected that the antibody will ... multata and bovine due to ...
... encodes two unrelated proteins both of which ... cell cycle in a p53-dependent manner. p14^ARF^ ... degradation of mdm2 proteinrequired for mdm2 modification ... This interaction is mediated by the exon ...
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
...
Biology Products: